Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 1
2006 1
2007 1
2008 2
2009 6
2010 7
2011 2
2012 3
2013 2
2014 1
2015 6
2016 4
2017 5
2018 8
2019 10
2020 10
2021 9
Text availability
Article attribute
Article type
Publication date

Search Results

66 results
Results by year
Filters applied: . Clear all
Page 1
The selective 5-HT(1A) receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques.
Depoortere R, Johnston TH, Fox SH, Brotchie JM, Newman-Tancredi A. Depoortere R, et al. Parkinsonism Relat Disord. 2020 Sep;78:151-157. doi: 10.1016/j.parkreldis.2020.08.009. Epub 2020 Aug 13. Parkinsonism Relat Disord. 2020. PMID: 32846366
METHODS: The effects of NLX-112 (0.03, 0.1 and 0.3 mg/kg PO) on established LID evoked by acute challenge with l-DOPA (27.5 3.8 mg/kg PO) were assessed in MPTP-treated cynomolgus macaques. Amantadine (10 mg/kg PO) was tested as a positive …
METHODS: The effects of NLX-112 (0.03, 0.1 and 0.3 mg/kg PO) on established LID evoked by acute challenge with l …
Serotonin 5-HT(1A) Receptor Biased Agonists Induce Different Cerebral Metabolic Responses: A [(18)F]-Fluorodesoxyglucose Positron Emission Tomography Study in Conscious and Anesthetized Rats.
Levigoureux E, Vidal B, Fieux S, Bouillot C, Emery S, Newman-Tancredi A, Zimmer L. Levigoureux E, et al. ACS Chem Neurosci. 2019 Jul 17;10(7):3108-3119. doi: 10.1021/acschemneuro.8b00584. Epub 2019 Jan 7. ACS Chem Neurosci. 2019. PMID: 30576601
Several 5-HT(1A) receptor biased agonists are currently in development, including NLX-101 (aka F15599) and NLX-112 (aka F13640, befiradol), with preclinical data suggesting that they preferentially target different populatio …
Several 5-HT(1A) receptor biased agonists are currently in development, including NLX-101 (aka F15599) and NL
NLX-112, a highly selective 5-HT(1A) receptor agonist: Effects on body temperature and plasma corticosterone levels in rats.
Newman-Tancredi A, Depoortère R, Carilla-Durand E, Tarayre JP, Kleven M, Koek W, Bardin L, Varney MA. Newman-Tancredi A, et al. Pharmacol Biochem Behav. 2018 Feb;165:56-62. doi: 10.1016/j.pbb.2017.11.002. Epub 2017 Nov 7. Pharmacol Biochem Behav. 2018. PMID: 29126856
NLX-112 (a.k.a. F13640 or befiradol), exhibits nanomolar affinity, exceptional selectivity and high agonist efficacy at 5-hydroxytryptamine 5-HT(1A) receptors. ...The increase in corticosterone induced by NLX-112 (0.63mg/kg
NLX-112 (a.k.a. F13640 or befiradol), exhibits nanomolar affinity, exceptional selectivity and high agonist effi
Pharmacological MRI to investigate the functional selectivity of 5-HT(1A) receptor biased agonists.
Vidal B, Bolbos R, Redouté J, Langlois JB, Costes N, Newman-Tancredi A, Zimmer L. Vidal B, et al. Neuropharmacology. 2020 Aug 1;172:107867. doi: 10.1016/j.neuropharm.2019.107867. Epub 2019 Nov 26. Neuropharmacology. 2020. PMID: 31783063
The cerebral blood oxygen level dependent (BOLD) signal changes induced by increasing doses of two serotonin 5-HT(1A) receptor biased agonists, NLX-112 and NLX-101, were mapped in anaesthetized rats. ...Importantly, NLX-101 had no …
The cerebral blood oxygen level dependent (BOLD) signal changes induced by increasing doses of two serotonin 5-HT(1A) receptor biased …
NLX-112, a highly selective 5-HT(1A) receptor agonist, mediates analgesia and antidepressant-like activity in rats via spinal cord and prefrontal cortex 5-HT(1A) receptors, respectively.
Newman-Tancredi A, Bardin L, Auclair A, Colpaert F, Depoortère R, Varney MA. Newman-Tancredi A, et al. Brain Res. 2018 Jun 1;1688:1-7. doi: 10.1016/j.brainres.2018.03.016. Epub 2018 Mar 16. Brain Res. 2018. PMID: 29555239
NLX-112 (a.k.a. F13640 or befiradol) possesses marked activity in a variety of animal models of pain and of neuropsychiatric disorders; it exhibits nanomolar affinity, exceptional selectivity and high agonist efficacy at 5-hydroxytryptamine1A (
NLX-112 (a.k.a. F13640 or befiradol) possesses marked activity in a variety of animal models of pain and of neur
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A. Iderberg H, et al. Exp Neurol. 2015 Sep;271:335-50. doi: 10.1016/j.expneurol.2015.05.021. Epub 2015 May 30. Exp Neurol. 2015. PMID: 26037043
Here, we describe the activity of a novel, highly selective and potent 5-HT1A agonist, NLX-112 (also known as befiradol or F13640) in rat models relevant to PD and its associated affective disorders. ...In microdialysis experiments, NLX- …
Here, we describe the activity of a novel, highly selective and potent 5-HT1A agonist, NLX-112 (also known as befira
Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT(1A) receptor agonist.
Newman-Tancredi A, Martel JC, Cosi C, Heusler P, Lestienne F, Varney MA, Cussac D. Newman-Tancredi A, et al. J Pharm Pharmacol. 2017 Sep;69(9):1178-1190. doi: 10.1111/jphp.12762. Epub 2017 Jun 14. J Pharm Pharmacol. 2017. PMID: 28612503
OBJECTIVES: NLX-112 (befiradol, F13640) is a selective serotonin 5-HT(1A) receptor agonist. ...NLX-112 was also tested on G-protein activation in rat hippocampal membranes. ...
OBJECTIVES: NLX-112 (befiradol, F13640) is a selective serotonin 5-HT(1A) receptor agonist. ...NLX
The selective 5-HT(1A) receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets.
Fisher R, Hikima A, Morris R, Jackson MJ, Rose S, Varney MA, Depoortere R, Newman-Tancredi A. Fisher R, et al. Neuropharmacology. 2020 May 1;167:107997. doi: 10.1016/j.neuropharm.2020.107997. Epub 2020 Feb 10. Neuropharmacology. 2020. PMID: 32057799 Free PMC article.
Reducing the activity of these neurons diminishes l-DOPA-induced dyskinesia (LID), but there are currently no clinically approved selective, high efficacy 5-HT(1A) receptor agonists. Here we describe the effects of NLX-112, a highly selective and efficacious …
Reducing the activity of these neurons diminishes l-DOPA-induced dyskinesia (LID), but there are currently no clinically approved selective, …
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
McCreary AC, Varney MA, Newman-Tancredi A. McCreary AC, et al. Neuropharmacology. 2016 Jun;105:651-660. doi: 10.1016/j.neuropharm.2016.01.013. Epub 2016 Jan 9. Neuropharmacology. 2016. PMID: 26777281
This is likely due to conversion of l-DOPA to dopamine as a 'false neurotransmitter' from serotoninergic neurons. The highly selective and efficacious 5-HT1A receptor agonist, NLX-112 (befiradol or F13640) shows potent activity in a rat model of …
This is likely due to conversion of l-DOPA to dopamine as a 'false neurotransmitter' from serotoninergic neurons. The highly selective and e …
Cortical 5-hydroxytryptamine 1A receptor biased agonist, NLX-101, displays rapid-acting antidepressant-like properties in the rat chronic mild stress model.
Depoortère R, Papp M, Gruca P, Lason-Tyburkiewicz M, Niemczyk M, Varney MA, Newman-Tancredi A. Depoortère R, et al. J Psychopharmacol. 2019 Nov;33(11):1456-1466. doi: 10.1177/0269881119860666. Epub 2019 Jul 10. J Psychopharmacol. 2019. PMID: 31290370
BACKGROUND: NLX-101 (also known as F15599) is a highly selective and efficacious 'biased' agonist at cortical 5-hydroxytryptamine 1A (5-HT(1A)) heteroreceptors. ...The effects of NLX-101 were maintained over the 2 week treat …
BACKGROUND: NLX-101 (also known as F15599) is a highly selective and efficacious 'biased' agonist at cortical 5- …
66 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page